An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
GLP-1 drugs — the class that includes Ozempic and Wegovy — are selling in Canada faster than ever and look likely to set a new annual sales record. That’s the basic news: prescriptions and purchases of these medicines have jumped, and revenue this year is tracking above previous peaks. GLP-1 drugs are medicines that copy a hormone your gut makes after you eat. That hormone talks to your brain to reduce appetite and to your stomach to slow how quickly it empties, which helps people eat less and feel full longer. Some products in this family are prescribed for type 2 diabetes, and at higher doses a few are approved specifically for weight loss. They are not simple vitamins — they are prescription medicines given by injection or, in some cases, by pill. The reporting is about sales data, not a new clinical trial. It shows more prescriptions and more spending on these drugs in Canada this year compared with past years. That increase reflects more people being prescribed GLP-1s, higher demand for weight-loss uses, and broader public awareness. The article doesn’t claim the drugs suddenly work better or that there’s new safety data — it’s financial and usage information. We don’t get patient-level results or long-term benefit numbers from this story; it’s about market trends. This matters because higher sales mean more people are using these medicines, and that affects access, public health planning, and government budgets. For individuals, it signals that doctors are more willing to prescribe GLP-1s and that your friends or coworkers might be using them. For policymakers and insurers, rising costs could trigger coverage debates: should public drug plans pay for these drugs for weight loss, and if so, for whom? Pharmacies and clinics may change how they operate to meet demand. There are important caveats. Sales data doesn’t tell us about long-term safety or who benefits most. GLP-1s can have side effects like nausea, diarrhea, and stomach issues, and they’re not appropriate for everyone; people with certain medical conditions or pregnant people should avoid them unless a doctor advises otherwise. There are also questions about what happens when people stop the drugs — weight often returns — and about equitable access if prices stay high. And while stronger sales suggest popularity, they don’t replace careful medical advice. Bottom line: GLP-1 drugs are being used more in Canada, driving record sales, but rising use raises practical, medical, and policy questions that money numbers alone can’t answer.
Source: The Globe and Mail